Denali Therapeutics Inc. Common Stock

DNLINASDAQ • USD
19.38 USD
↘ 1.27 (6.15%)AT CLOSE (11:59 AM EDT)
19.39
↘ 0.09 (0.46%)
POST MARKET (AS OF 06:40 PM EDT)
Post Market
AS OF 06:40 PM EDT
19.39
↘ 0.09 (0.46%)
🟢Market: OPEN
Open?$20.60
High?$20.80
Low?$19.22
Prev. Close?$20.65
Volume?1.8M
Avg. Volume?1.9M
VWAP?$19.77
Rel. Volume?0.96x
Bid / Ask
Bid?$19.38 × 100
Ask?$19.40 × 300
Spread?$0.02
Midpoint?$19.39
Valuation & Ratios
Market Cap?3.3B
Shares Out?158.6M
Float?126.3M
Float %?86.1%
P/E Ratio?N/A
P/B Ratio?3.23
EPS?-$3.23
Dividend?0.00%
Ex-Dividend?N/A
Technical Outlook
Loading...
Fundamental Outlook
Loading...
Short Interest
Loading...
Financial Health
Current Ratio?9.16Strong
Quick Ratio?9.16Strong
Cash Ratio?2.09Strong
Debt/Equity?0.01Low
ValuationATTRACTIVELY VALUED
Score
83/100
P/E?
N/A▾
P/B?
3.23FAIR▾
P/S?
N/A▾
P/FCF?
N/A▾
EV/EBITDA?
-5.7CHEAP▾
EV/Sales?
N/A▾
Returns & Efficiency
ROE?
-50.6%WEAK▾
ROA?
-44.8%WEAK▾
Cash Flow & Enterprise
FCF?$-422102000
Enterprise Value?$3.1B
Related Companies
Loading...
News
Profile
Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegenerative diseases. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others. The Company has one operating segment with the goal to discover, develop, and commercializing therapeutics.
Employees
503
Market Cap
3.3B
Industry
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Website
www.denalitherapeutics.com
Listed
2017-12-08
Address
161 OYSTER POINT BLVD.
SOUTH SAN FRANCISCO, CA 94080
Phone: (650) 866-8547
MarketsMoversWatchlist